Breaking News
Investing Pro 0
Free Webinar - What Is a Gold IRA? Fees, Advantages, and Risks - December 7, 2022 | 01:00PM EST Enroll Now

Biden will nominate industry-friendly Califf to lead U.S. FDA

Sports & General Nov 12, 2021 04:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Food and Drug Administration Commissioner nominee Doctor Robert Califf testifies at his nomination hearing at the Senate Health, Education, Labor and Pensions Committee on Capitol Hill in Washington, November 17, 2015. REUTERS/Gary Cameron/Fil
 
LLY
+0.93%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GOOGL
-2.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
+0.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIIB
+0.23%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CYTK
+0.11%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GOOG
-2.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Andrea Shalal and Ahmed Aboulenein

WASHINGTON (Reuters) - President Joe Biden on Friday said he would nominate Robert Califf for a second stint as commissioner of the U.S. Food and Drug Administration, and urged the Senate to swiftly confirm him.

Califf, 70, a well-regarded cardiologist and researcher closely linked with the pharmaceutical industry, served as FDA commissioner from February 2016 until the end of then-President Barack Obama's second term in January 2017.

"Dr. Robert Califf is one of the most experienced clinical trialists in the country, and has the experience and expertise to lead the Food and Drug Administration during a critical time in our nation's fight to put an end to the coronavirus pandemic," Biden said in a statement issued by the White House.

Califf was confirmed for his first term by the Senate 89-4 with broad bipartisan support, though at the time he faced criticism from some Democrats, like Senators Bernie Sanders of Vermont and Joe Manchin of West Virginia, who said his ties to the drug industry made him unfit to regulate it impartially.

At the time, Califf had co-authored papers with industry executives and served as a consultant for drugmakers. He was since hired by Google parent Alphabet (NASDAQ:GOOGL) Inc in 2019, and currently serves as the head of Clinical Policy and Strategy across its Google Health and Verily Life Sciences enterprises.

He is also on the board of drugmaker Cytokinetics (NASDAQ:CYTK) Inc and has received consulting fees from pharmaceutical companies Amgen Inc (NASDAQ:AMGN), Boehringer Ingelheim, Biogen Inc (NASDAQ:BIIB), Eli Lilly (NYSE:LLY) and Co, Roche AG's Genentech unit, and Merck & Co Inc.

"Dr. Califf had strong bipartisan support in the Senate in 2016, and I urge the Senate to swiftly confirm Dr. Califf so he can continue the important work being done at this critical moment," Biden said in the White House statement.

The leading U.S. pharmaceutical trade association welcomed his nomination.

"We hope the confirmation process will proceed quickly, and we look forward to continuing to work with the FDA as we fight the pandemic and other deadly diseases," said Pharmaceutical Research and Manufacturers of America President Steve Ubl.

SENATE CONFIRMATION

Democrats have a razor-thin majority in the Senate. Manchin said on Friday he would oppose Califf's nomination.

"Dr. Califf's nomination and his significant ties to the pharmaceutical industry take us backwards not forward," Manchin said in a statement on Friday.

White House Press Secretary Jen Psaki said the Biden administration was confident Califf would be confirmed, pointing to his experience and prior confirmation.

"We feel he's a qualified person who has the exact experience for this moment," Psaki said at a briefing, adding that Manchin had ultimately voted to confirm him in 2015.

The FDA has been without a permanent leader since Biden took office in January.

If confirmed by the Senate, Califf will take over from longtime FDA veteran Janet Woodcock, who has been serving as acting commissioner. The FDA oversees everything from medicine and medical devices to food, tobacco and cosmetics.

Woodcock has been in the role since Biden took office but legally could not serve past Monday unless a permanent nominee was named. Biden thanked her for her work over the past year.

The FDA has been in the spotlight as it reviews vaccines and potential treatments for COVID-19, and came under additional scrutiny for its accelerated approval this year of Biogen Inc's Alzheimer's drug, Aduhelm, against the recommendation of its outside expert advisers.

Califf is an internationally recognized expert in clinical trial research, health disparities, healthcare quality, and cardiovascular medicine, the White House said. He is a longtime faculty member at Duke University where he founded the Duke Clinical Research Institute, a large academic center that received over half its funding from the drug industry.

He joined the FDA in 2015 as deputy commissioner for Medical Products and Tobacco and worked closely with then-Vice President Biden on Cancer Moonshot, an initiative aimed at speeding development of cancer treatments.

(This story fixes typo in subhed.)

Biden will nominate industry-friendly Califf to lead U.S. FDA
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Alan Rice
Alan Rice Nov 14, 2021 2:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So, remember kids: Just say "Yes !! to.....
Alan Rice
Alan Rice Nov 14, 2021 2:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's SARCASM !! ( Don't say "Yes" to drugs if you wish to have a GOOD life.)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email